Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Cost-effectiveness of low-molecular-weight heparin for treatment of pulmonary embolism.

Aujesky D, Smith KJ, Cornuz J, Roberts MS.

Chest. 2005 Sep;128(3):1601-10.

PMID:
16162764
2.
3.

Cost-effectiveness of dalteparin vs unfractionated heparin for the prevention of venous thromboembolism in critically ill patients.

Fowler RA, Mittmann N, Geerts W, Heels-Ansdell D, Gould MK, Guyatt G, Krahn M, Finfer S, Pinto R, Chan B, Ormanidhi O, Arabi Y, Qushmaq I, Rocha MG, Dodek P, McIntyre L, Hall R, Ferguson ND, Mehta S, Marshall JC, Doig CJ, Muscedere J, Jacka MJ, Klinger JR, Vlahakis N, Orford N, Seppelt I, Skrobik YK, Sud S, Cade JF, Cooper J, Cook D; Canadian Critical Care Trials Group; Australia and New Zealand Intensive Care Society Clinical Trials Group.

JAMA. 2014 Nov 26;312(20):2135-45. doi: 10.1001/jama.2014.15101.

PMID:
25362228
4.

Economic and utilization outcomes associated with choice of treatment for venous thromboembolism in hospitalized patients.

Knight KK, Wong J, Hauch O, Wygant G, Aguilar D, Ofman JJ.

Value Health. 2005 May-Jun;8(3):191-200.

5.
6.

Cost-effectiveness of low-molecular-weight heparin and unfractionated heparin in treatment of deep vein thrombosis.

Rodger M, Bredeson C, Wells PS, Beck J, Kearns B, Huebsch LB.

CMAJ. 1998 Oct 20;159(8):931-8.

7.

Treatment of pulmonary embolism: The use of low-molecular-weight heparin in the inpatient and outpatient settings.

Hull RD.

Thromb Haemost. 2008 Mar;99(3):502-10. doi: 10.1160/TH07-08-0500. Review.

PMID:
18327398
8.

Cost-minimization analysis of low-molecular-weight heparin (dalteparin) compared to unfractionated heparin for inpatient treatment of cancer patients with deep venous thrombosis.

Avritscher EB, Cantor SB, Shih YC, Escalante CP, Rivera E, Elting LS.

Support Care Cancer. 2004 Jul;12(7):531-6. Epub 2004 Feb 21.

PMID:
14986076
9.

Hospital-based costs associated with venous thromboembolism treatment regimens.

Merli G, Ferrufino C, Lin J, Hussein M, Battleman D.

J Thromb Haemost. 2008 Jul;6(7):1077-86. doi: 10.1111/j.1538-7836.2008.02997.x. Epub 2008 Jul 1.

10.

Pharmacoeconomics of low-molecular-weight heparins: limitations of studies comparing them to unfractionated heparin.

Jones TE, Smith BJ, Polasek JF.

Expert Opin Pharmacother. 2004 Sep;5(9):1887-97. Review.

PMID:
15330727
11.

A probabilistic cost-effectiveness analysis of enoxaparin versus unfractionated heparin for the prophylaxis of deep-vein thrombosis following major trauma.

Lynd LD, Goeree R, Crowther MA, O'Brien BJ.

Can J Clin Pharmacol. 2007 Summer;14(2):e215-26. Epub 2007 Jun 6.

PMID:
17652767
12.

Low-molecular-weight heparin versus unfractionated heparin for prophylaxis of venous thromboembolism in medicine patients--a pharmacoeconomic analysis.

Wilbur K, Lynd LD, Sadatsafavi M.

Clin Appl Thromb Hemost. 2011 Oct;17(5):454-65. doi: 10.1177/1076029610376935. Epub 2010 Aug 10.

PMID:
20699258
13.
14.

Economic evaluation of the prophylaxis for thromboembolism in critical care trial (E-PROTECT): study protocol for a randomized controlled trial.

Fowler RA, Mittmann N, Geerts WH, Heels-Ansdell D, Gould MK, Guyatt G, Krahn M, Finfer S, Pinto R, Chan B, Ormanidhi O, Arabi Y, Qushmaq I, Rocha MG, Dodek P, McIntyre L, Hall R, Ferguson ND, Mehta S, Marshall JC, Doig CJ, Muscedere J, Jacka MJ, Klinger JR, Vlahakis N, Orford N, Seppelt I, Skrobik YK, Sud S, Cade JF, Cooper J, Cook D; Canadian Critical Care Trials Group; Australia and New Zealand Intensive Care Society Clinical Trials Group.

Trials. 2014 Dec 20;15:502. doi: 10.1186/1745-6215-15-502.

15.

Cost-effectiveness of low-molecular-weight heparin for secondary prophylaxis of cancer-related venous thromboembolism.

Aujesky D, Smith KJ, Cornuz J, Roberts MS.

Thromb Haemost. 2005 Mar;93(3):592-9.

PMID:
15735815
16.

Cost effectiveness of anticoagulation in acute coronary syndromes.

Latour-Pérez J, de-Miguel-Balsa E.

Pharmacoeconomics. 2012 Apr;30(4):303-21. doi: 10.2165/11589290-000000000-00000. Review.

PMID:
22409291
17.

Cost effectiveness of tinzaparin sodium versus unfractionated heparin in the treatment of proximal deep vein thrombosis.

Caro JJ, Getsios D, Caro I, O'Brien JA.

Pharmacoeconomics. 2002;20(9):593-602.

PMID:
12141887
18.

Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.

Holzheimer RG.

Eur J Med Res. 2004 Apr 30;9(4):225-39. Review.

PMID:
15210403
19.

An economic evaluation of the costs and benefits of heparin rationalisation in a hospital pharmacy.

Reeves P, Cooke J, Lloyd A, Hutchings A.

Pharm World Sci. 2004 Jun;26(3):160-8.

PMID:
15230364
20.

Supplemental Content

Support Center